Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-05-29

DEVELOPMENT OF NOVEL ANIMAL MODELS OF GLUTAMATERGIC CENTRAL NERVOUS SYSTEM DISORDERS USING IN VIVO SIRNA AND TRANSGENIC APPROACHES

Cel

Glutamate is the most abundant excitatory transmitter in the brain. However, very few models exist to explore the potential of drugs that modulate glutamate transmission. Because altered glutamate transmission is involved in numerous psychiatric diseases, there is a strong need for such models, to characterise the effects of hypo- and hyper-glutamatergic states on the onset and development of such diseases. AGLAEA will develop and characterise models of selective, partial knockdown of specific components of the brain glutamatergic system in mice. This will provide better comprehension of the implication of glutamate signalling in diseases such as schizophrenia, anxiety and cognitive disorders. AGLAEA will lead to breakthrough research on the neurobiological and neurochemical bases of psychiatric disorders and will enable the further testing of new drugs for treatment. In order to selectively turn off specific components of the glutamatergic pathways, an siRNA approach will be used. The effect of modulation of glutamate signalling will be characterised using functional MRI (fMRI) and microdialysis/microsensor analysis. Specific behavioural tests will be carried out on live animals for the assessment of glutamate-related psychiatric disorders. Furthermore, the data collected from siRNA experiments will be applied to the generation of transgenic mice, in which modulation of glutamate signaling will be induced at different stages of development. Therefore, AGLAEA will provide both the pharmaceutical and the academic world with potent models. These models will be used to test novel compounds and assess their therapeutic value and will benefit researchers investigating the neurobiological and neurochemical bases of those diseases.
The consortium set up to reach the objectives of AGLAEA gathers 3 high tech SMEs, 2 academic groups and one large group for the management of the project (ALMA), representing all together 4 European countries (FR, HU, UK, NL).

Dziedzina nauki (EuroSciVoc)

Program(-y)

Temat(-y)

Zaproszenie do składania wniosków

FP6-2005-LIFESCIHEALTH-7
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

STREP - Specific Targeted Research Project

Koordynator

ADDEX PHARMACEUTICALS FRANCE SAS
Wkład UE
Brak danych
Koszt całkowity
Brak danych

Uczestnicy (5)